{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-003070","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.535138+00:00","generated_at":"2026-05-27T00:57:06.816405+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eton awarded patent for ET-600 desmopressin oral solution expiring 2044; NDA filing expected Q2 2025","bullets":["USPTO granted U.S. Patent No. 12,214,010 covering ET-600's proprietary desmopressin oral solution formulation.","Patent expires in 2044 and is expected to be listed in FDA Orange Book upon product approval.","ET-600 treats diabetes insipidus; no FDA-approved oral liquid currently available for pediatric patients.","Pivotal bioequivalence study ongoing; results expected at end of February 2025.","If positive, NDA filing with FDA anticipated by Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-003070","json":"https://secwatch.observer/filing/0001437749-25-003070.json","markdown":"https://secwatch.observer/filing/0001437749-25-003070.md","text":"https://secwatch.observer/filing/0001437749-25-003070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/0001437749-25-003070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/eton20250203_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:57:06.816405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}